2-(2-(4-(3,4-dichlorophenyl)thiazol-2-yl)hydrazono)-3-(2-nitrophenyl)propanoic acid | 901787-86-8

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 苯丙酸
• 英文名称: 2-(2-(4-(3,4-dichlorophenyl)thiazol-2-yl)hydrazono)-3-(2-nitrophenyl)propanoic acid
• 英文别名: (E)-2-{[4-(3,4-dichloro-phenyl)-thiazol-2-yl]-hydrazono}-3-(2-nitro-phenyl)-propionic acid；(2E)-2-[[4-(3,4-dichlorophenyl)-1,3-thiazol-2-yl]hydrazinylidene]-3-(2-nitrophenyl)propanoic acid
• CAS: 901787-86-8
• 化学式: C₁₈H₁₂Cl₂N₄O₄S
• 分子量: 451.29
• InChiKey: KFRKRECSIYXARE-HYARGMPZSA-N

物化性质

• 沸点：
  668.9±65.0 °C(Predicted)
• 密度：
  1.58±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  6.1
• 重原子数：
  29
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  149
• 氢给体数：
  2
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  α-[2-[4-(3,4-dichlorophenyl)-2-thiazolyl]hydrazinylidene]-2-nitrobenzenepropanoic acid 以 水 、 溶剂黄146 、 乙腈 为溶剂， 生成 2-(2-(4-(3,4-dichlorophenyl)thiazol-2-yl)hydrazono)-3-(2-nitrophenyl)propanoic acid 、 2-(2-(4-(3,4-dichlorophenyl)thiazol-2-yl)hydrazono)-3-(2-nitrophenyl)propanoic acid
  参考文献：
  名称：

  Regulation of protein synthesis

  摘要：

  一种用于抑制肿瘤细胞增殖的组合物和方法，与非肿瘤细胞相比。还描述了筛选抑制依赖帽结构翻译而非独立帽结构翻译蛋白质的组合物的方法。

  公开号：

  US20100144805A1

文献信息

• BENZOIC ACID DERIVATIVES
  申请人：Gillespie Paul

  公开号：US20130079346A1

  公开（公告）日：2013-03-28

  There are disclosed are compounds of the formula: wherein R1 and R2 are as disclosed herein, which are eIF4E inhibitors useful in the treatment of cancers. Also disclosed are compositions comprising the compounds, as well as methods of treating cancer using the compounds.

  已披露的化合物的公式如下：其中R1和R2如本文所述，它们是eIF4E抑制剂，可用于治疗癌症。还披露了包含这些化合物的组合物，以及使用这些化合物治疗癌症的方法。
• Compounds for the Inhibition of Cellular Proliferation
  申请人：Chorev Michael

  公开号：US20130178505A1

  公开（公告）日：2013-07-11

  Compositions and methods for inhibiting translation are provided. Compositions, methods and kits for treating (1) cellular proliferative disorders, (2) non-proliferative, degenerative disorders, (3) viral infections, (4) disorders associated with viral infections, and/or (5) non-proliferative metabolic disorders such as type II diabetes where inhibition of translation initiation is beneficial using the compounds disclosed herein.

  提供了抑制翻译的组合物和方法。本文披露的化合物可用于治疗以下疾病：（1）细胞增殖性疾病，（2）非增殖性退行性疾病，（3）病毒感染，（4）与病毒感染有关的疾病，以及（5）非增殖性代谢性疾病，如II型糖尿病，其中抑制翻译起始有益。本文还提供了用于治疗上述疾病的方法和试剂盒。
• Structure–activity relationship study of 4EGI-1, small molecule eIF4E/eIF4G protein–protein interaction inhibitors
  作者：Khuloud Takrouri、Ting Chen、Evangelos Papadopoulos、Rupam Sahoo、Eihab Kabha、Han Chen、Sonia Cantel、Gerhard Wagner、Jose A. Halperin、Bertal H. Aktas、Michael Chorev

  DOI：10.1016/j.ejmech.2014.03.034

  日期：2014.4

  Protein-protein interactions are critical for regulating the activity of translation initiation factors and multitude of other cellular process, and form the largest block of untapped albeit most challenging targets for drug development. 4EGI-1, (E/Z)-2-(2-(4-(3,4-dichlorophenyl)thiazol-2-yl)hydrazono)-3-(2-nitrophenyl)propanoic acid, is a hit compound discovered in a screening campaign of small molecule libraries as an inhibitor of translation initiation factors elF4E and eIF4G protein protein interaction; it inhibits translation initiation in vitro and in vivo. A series of 4EGI-1-derived thiazol-2-yl hydrazones have been designed and synthesized in order to delineate the structural latitude and improve its binding affinity to eIF4E, and increase its potency in inhibiting the eIF4E/eIF4G interaction. Probing a wide range of substituents on both phenyl rings comprising the 3-phenylpropionic acid and 4-phenylthiazolidine moieties in the context of both E- and Z-isomers of 4EGI-1 led to analogs with enhanced binding affinity and translation initiation inhibitory activities. (C) 2014 Elsevier Masson SAS. All rights reserved.
• REGULATION OF PROTEIN SYNTHESIS BY INHIBITION OF EIF4E-EIF4G INTERACTION
  申请人：President and Fellows of Harvard College

  公开号：EP1868604A2

  公开（公告）日：2007-12-26
• PHARMACEUTICAL COMPOUNDS AND USES THEREOF
  申请人：Yang DaQing

  公开号：US20200069712A1

  公开（公告）日：2020-03-05

  Described herein are compounds pharmaceutically acceptable salts, isomers, mixture of isomers, crystalline forms, non-crystalline forms, hydrates, or solvates thereof, as well as methods using those compounds to, among other things, treat cancer.